Tysabri® Subkutan
Basert på 15 års erfaring med Tysabri IV lanserer vi nå Tysabri som en subkutan injeksjon — 150 mg x 2.1 Medikamentet er det samme som Tysabri IV og effekten av behandlingen er sammenlignbar med Tysabri IV, men administrasjonen er enklere og mer fleksibel.1-7 Tysabri er indisert som sykdomsmodifiserende monoterapi hos voksne med svært aktiv relapserende remitterende multippel sklerose (RRMS).1
Referanser
1. Tysabri (natalizumab) SPC 12/2023, avsnitt 4.1.
2. Trojano M, Ramió-Torrentà L, Grimaldi LM, et al. A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal. April 2021; 27(14):2240-2253.
3. Plavina T, Fox EJ, Lucas N, et al. A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis. J Clin Pharmacol. 2016 Oct; 56(10):1254-1262.
4. Santus P, Ferrando M, Baiardini I, et al. Patients beliefs on intravenous and subcutaneous routes of administration of biologics for severe asthma treatment: A cross-sectional observational survey study. World Allergy Organ J. 2019; 12(4):100030.
5. Rummel M, Kim TM, Aversa F, et al. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab). Ann Oncol. 2017; 28(4):836-842.
6. Tetteh EK and Morris S. Evaluating the administration costs of biologic drugs: development of a cost algorithm. Health Economics Review. 2014; 4(26).
7. Wright JM and Jones GB. Developing the Subcutaneous Drug Delivery Route. Medical Research Archives. 2017; 5(12):1-12.